Bronchiectasis

Evidence-based Respiratory Medicine

Volumn , Issue , 2007, Pages 349-360

  Kolbe, John ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Acute exacerbations; Airway clearance techniques; Bronchiectasis; Mucolytics; Pathophysiology

Indexed keywords

EID: 80052665564     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987377.ch28     Document Type: Chapter

References (112)

1. Lapa de Silva JR, Jones JAH,Cole PJ, Poulter LW. The immunological component of the cellular inflammatory infiltrate in bronchiectasis. Thorax 1989; 44:668-73.
2. Cole P. Bronchiectasis. In: Brewis RAL, Corrin B, Geddes DM, Gibson GJ, eds. Respiratory Medicine. 2nd edn. Saunders, 1995:1289-93.
3. Becroft DMO. Histopathology of fatal adenovirus infection of the respiratory tract in young children. J Clin Pathol 1967: 20: 561-9.
4. Becroft DMO. Bronchiolitis obliterans,bronchiectasis and other sequelae of adenovirus type 21 infection in young children. J Clin Pathol 1971; 24:72-82.
5. WhyteKF,Williams GR. Bronchiectasis after mycoplasma pneumonia. Thorax 1984; 39:390-1.
6. Whitwell F. A study of the pathology and pathogenesis of bronchiectasis. Thorax 1952; 7:213-39.
7. Reiff DB,Wells AU, Carr DH, Cole PJ,Hansell DM. CT findings in bronchiectasis: value in distinguishing between idiopathic and specific types. AJR 1995; 165:261-7.
8. Kolbe J,Wells AU. Bronchiectasis: a neglected cause of respiratory morbidity and mortality. Respirology 1996; 1:221-5.
9. Wakefield St J, Waite D. Abnormal cilia in Polynesians with bronchiectasis. AmRev Respir Res 1980; 121:1003-9.
10. Barker AF. Medical progress: bronchiectasis. N Engl J Med 2002; 346:1383-93.
11. O'Brien C, Guest PJ,Hill SJ, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000; 55:635-42.
12. Nath AR, Capel LH. Lung crackles in bronchiectasis. Thorax 1980; 35:694-9.
13. Currie DC, Cooke JC, Morgan DA et al. Interpretation of bronchograms and chest radiographs in patients with chronic sputum production. Thorax 1987; 42:278-84.
14. Grenier P,Maurice F,Mussel D et al. Bronchiectasis: assessment by thin section CT. Radiology 1986; 161:95-9.
15. Joharjy JA, Bashi SA,Abdullah AK. Value of medium thickness CT in the diagnosis of bronchiectasis. AJR 1987; 149:113-17.
16. Roberts HR, Wells AU, Milne DG et al. Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests. Thorax 2000; 55:198-204.
17. Remy-Jardin M, Remy J, Cortet B, Mauri F, Delcambre B. Lung changes in rheumatoid arthritis: CT findings. Radiology 1994; 193:375-82.
18. Carter B, Perez T, Roux N et al. Pulmonary function tests and high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56:596-600.
19. Kraft SC, Earle RH, Roesler M et al. Unexplained bronchopulmonary disease with inflammatory bowel disease. Arch Intern Med 1976; 136:454-9.
20. Butland RJ, Cole P, Citron KM, Turner-Warwick M. Chronic bronchial suppuration and inflammatory bowel disease. Q J Med 1981; 197:63-75.
21. Eaton TE, Lambie N,Wells AU. Bronchiectasis following colectomy for Crohn's disease. Thorax 1998; 53:529-31.
22. Mahadeva R, Flower C, Shneerson J. Bronchiectasis in association with coeliac disease. Thorax 1998; 53:527-9.
23. Haeney M. Intravenous immune globulin in primary immunodeficiency. Clin Exp Immunol 1994; 97(Suppl):11-15.
24. Skull S, Kemp A. Treatment of hypogammaglobulinaemia with intravenous immunoglobulin. Arch Dis Child 1996; 74:527-30.
25. Hill SL,Mitchell JL, Burnett D, Stockley RA. IgG subclasses in the serum and sputum from patients with bronchiectasis. Thorax 1998; 53:463-8.
26. Eaton T, Garrett J, Milne D, Frankel A, Wells AU. Allergic bronchopulmonary aspergillosis in the asthma clinic. A prospective evaluation of CT in the diagnostic algorithm. Chest 2000; 118:66-72.
27. Gervais R, Lafitte J-J, Dunmur V et al. Sweat chloride and ??F508 mutation in chronic bronchitis or bronchiectasis. Lancet 1993; 342:997.
28. Giroden E, Cazeneune C, Lebargy F et al. CFTR gene mutations in adults with disseminated bronchiectasis. Eur J Hum Genet 1997; 5:149-55.
29. King PT, Forshaw K, Du Sart D, Freezer NJ,Holmes PJ,Holdsworth SR. Prevalence of cystic fibrosis mutations in adult bronchiectasis. AmJ Respir Crit Care Med 2003; 167:A994.
30. Penketh ARL,Wise A,Mearns MB et al. Cystic fibrosis in adolescents and adults. Thorax 1987: 42:912-30.
31. Gan K,Guess WP,Bakker W et al. Genetic and clinical features of patients diagnosed with cystic fibrosis after the age of 16 years. Thorax 1995; 50:1301-4.
32. Kharitonov S,Wells AU,O'Connor B et al. Elevated levels of exhaled nitric oxide in bronchiectasis. Am J Respir Crit Care Med 1995; 151:1889-93.
33. Ho LP, Innes JA,Greening AP. Exhaled nitric oxide is not elevated in the inflammatory airways diseases of cystic fibrosis and bronchiectasis. Eur Respir J 1998; 12:1290-4.
34. Tsang KW,Leung R,Fung PC et al. Exhaled and sputum nitric oxide in bronchiectasis. Correlation with clinical parameters. Chest 2002; 121:88-94.
35. Moody A,Fergusson W,Wells A,Milne D,Kolbe J. Prevalence of airway hyperresponsiveness and predictors of responsiveness in idiopathic bronchiectasis. Respiratory 2002; 7:A35.
36. Horvath I, Loukides S,Wodehouse T et al. Comparison of exhaled and nasal nitric oxide and exhaled carbon monoxide levels in bronchiectatic patients with and without primary ciliary dyskinesia. Thorax 2003; 58:68-72.
37. Chang AB, Grimwood K, Mulholland EK, Torzillo PJ, for the Working Group on Indigenous Pediatric Respiratory Health. Bronchiectasis in indigenous children in remote Australian communities. Med J Aust 2002; 177:200-4.
38. King PT, Freezer NJ, Holdsworth SR, Holmes PW. Long-term prospective study of outcome in adult bronchiectasis. Am J Respir Crit Care Med 2003; 167:A223.
39. Pujana I, Gallego L, Martin G, Lopez F, Conduela J, Cisterna R. Epidemiological analysis of sequential Pseudomonas aeruginosa isolates from bronchiectasis patients without cystic fibrosis. J Clin Microbiol 1999; 37:2071-3.
40. Wilson CB, Jones PW,O'Leary CJ,Hansell DM, Cole PJ,Wilson R. Effect of spectrum of bacteriology on the quality of life to patients with bronchiectasis. Eur Respir J 1997; 10:1754-60.
41. Mishiel KA,Wells AU, Rubens MB, Cole PJ,Hansell DM. Effects of airway infection by Pseudomonas aeruginosa: a computed tomography study. Thorax 1997; 52:260-4.
42. Evans SA, Turner SM, Bosch BJ, Hardy CC,Woodhead MA. Lung function in bronchiectasis the influence of Pseudomonas aeruginosa. Eur Respir J 1996; 9:1601-4.
43. Amitani R,Wilson R, Rutman A et al. Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium. AmJ Respir Cell Mol Biol 1991; 4:26-32.
44. Tsang KWT,Rutman A,Tanaka A et al. Interaction of Pseudomonas aeruginosa with human respiratory mucosa in vitro. Eur Respir J 1994; 7:1746-53.
45. Swensen SJ, Hartman TE, Williams DE. Computed tomographic diagnosis of Mycobacterium avium-intracellulare complex in patients with bronchiectasis. Chest 1994; 105:49-52.
46. Wallace RJ Jr, Glassroth J,Griffith DE,Olivier KN,Cooke JL,Gordin F. Diagnosis and treatment of disease caused by non-tuberculous mycobacteria. Am J Respir Crit Care Med 1997; 156(Suppl):S1-S25.
47. Chan CH,Ho AK, Chan RC,Cheung H, Cheng AF. Mycobacteria as a cause of infective exacerbation in bronchiectasis. Postgrad Med J 1992; 68:896-9.
48. Redelmeier DA,Bayoumi AM,Goldstein RS,Guyatt GH. Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997; 155:1278-82.
49. Singh SL,Morgan MDL, Scott S,Walters D,Hardman AE. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992; 47:1019-24.
50. Wilson CB, Jones PW,O'Leary CJ, Cole PJ,Wilson R. Validation of the St George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997; 156:536-41.
51. Angill J, Agusti C, De Celis R et al. Bronchial inflammation and colonisation in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001; 164:1628-32.
52. Stockley RA, Bayley D,Hill SL,Hill AT, Croaks S, Campbell EJ. Assessment of airway neutrophils by sputum colour: correlation with airway inflammation. Thorax 2001; 56:366-72.
53. Kolbe J. Psychosocial influences on adherence to self-management plans. Dis Man Health Outcomes 2002; 10:551-70.
54. Sharples LD, Edmunds J, Bilton D et al. A randomised controlled cross-over trial of nurse practitioner versus doctor led outpatient care in a bronchiectasis clinic. Thorax 2002; 57:661-6.
55. Currie DC, Pavia D, Agnew JE et al. Impaired tracheobronchial clearance in bronchiectasis. Thorax 1987; 42:126-30.
56. Jones AP, Rowe BH. Bronchopulmonary hygiene physical therapy for chronic obstructive pulmonary disease and bronchiectasis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
57. Hess DR. The evidence for secretion clearance techniques. Respir Care 2001; 46:1276-93.
58. O'Neill B,Bradley JM,McArdle N,MacMahon J. The current physiotherapy management of patients with bronchiectasis: a UK survey. Int J Clin Pract 2002: 56:34-5.
59. Thompson CS,Harrison S,Ashley J,Day K, Smith DL. Randomised cross-over study of the Flutter device and the active cycle of breathing technique and non-cystic fibrosis bronchiectasis. Thorax 2002; 57:446-8.
60. Girard JP, Terki N. The Flutter VRP1: a new personal pocket therapeutic device used as an adjunct to drug therapy in the management of bronchial asthma. J Invest Allergol Clin Immunol 1994: 4:23-7.
61. King M. Mucoactive therapy: what the future holds for patients with cystic fibrosis. Pediatr Pulmol 1997; 24:122-3.
62. Daviskas E,Anderson SD,Brannan JD,Chan HK,Eberl S,Bautovich G. Inhalation of dry powder mannitol increases muco-ciliary clearance. Eur Respir J 1997; 10:2449-54.
63. Daviskas E,Anderson SD, Eberl S, Chan H-K, Bautovich G. Inhalation of dry power mannitol improves clearance ofmucus in patients with bronchiectasis. AmJ Respir Crit Care Med 1999; 159:1843-8.
64. Wills P,Hall R, Chan W-M, Cole PJ. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea. J Clin Invest 1997; 99:9-13.
65. Daviskas E, Anderson SD, Jonda I et al. Inhalation of hypertonic saline enhances muco-ciliary clearance in asthmatic and healthy subjects. Eur Respir J 1996; 9:725-32.
66. Bahous J,Carter A, Pincau L et al. Pulmonary function tests and airway responsiveness to methacholine in chronic bronchiectasis of the adult. Bull Eur Physiopathol Respir 1984; 20:375-80.
67. Pong J, Chan HS, Sung JY. Prevalence of asthma, atopy and bronchial hyperreactivity in bronchiectasis: a controlled study. Thorax 1989; 44:948-51.
68. Poole PJ, Black, PN. Mucolytic agents for chronic bronchitis [systematic review]. Cochrane Airways Group Cochrane Database Syst Rev 2003; 1.
69. Wills PJ,Wodehouse T, Corkery K,Mallon K. Short term recombinant human DN'ase in bronchiectasis. Am J Respir Crit Care Med 1996; 154:413-17.
70. Shah S,Capon DJ,Hellmiss R,Marsters SA,Baker CL. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87:9188-92.
71. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolised recombinant human DN'ase I. Chest 1998; 113:1329-34.
72. Bradley J,Moran F,Greenstone M. Physical training for bronchiectasis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford, Update Software, 2003.
73. Young P, Fergusson W, Drewse M, Kolbe J. Improvements in outcomes for chronic obstructive pulmonary disease attributable to a hospital-based respiratory rehabilitation programme. Aust NZ J Med 1999; 29:59-65.
74. Currie DC, Garbett ND, Chan KL et al. Double-blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis. Q J Med 1990; 76:799-816.
75. Orriols R, Roig J, Ferrer J et al. Inhaled antibiotic therapy in noncystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med 1999; 93:476-80.
76. Lin HC, Chen HF, Wong CH, Liu CY, Yu CT, Kuo HP. Inhaled gentamicin reduces airway neutrophil activity and mucus hypersecretion in bronchiectasis. Am J Respir Crit Care Med 1997; 155:2024-9.
77. Barker AF, Cough L, Fiel SB et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. AmJ Respir Crit Care Med 2000; 162:481-5.
78. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmon 2001; 31:464-73.
79. Takizawa H,Desaki M,Ohtashi T et al. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. AmJ Respir Crit Care Med 1997; 156:266-71.
80. Khan AA, Slifer TR, Araujo FG et al. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents 1999; 11:121-32.
81. Wozniak DJ, Kayser R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 2004; 125:625-69.
82. Hoiby H. Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax 1994; 49:531-2.
83. Wolter J, Seeney S, Bell S,Bowler S,Mosel P,McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57:212-16.
84. Equi A, Balfour-Lynn IM, Bush A, Rosethal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled, crossover trial. Lancet 2002; 360:978-84.
85. Tsang KW,Ho P-I, Chen K-N et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999; 13:361-4.
86. Koh YY, Lee MH, Sun YH, Sung KW, Chae JH. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 1997; 10:994-9.
87. Auerbach HS,Williams M,Kilpatrick JA,Colten HR. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985; 2:686-8.
88. Eigen H,Rosenstein BJ, Fitzsimmons S,Schidlow DV and the Cystic Fibrosis Foundation Prednisone Trial Group. A multicentre study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995; 126:515-23.
89. Lasserton T,Holt K,Greenstone M. Oral steroids for bronchiectasis (stable and acute exacerbations) (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
90. Kolbe J, Wells A, Ram FSF. Inhaled steroids for bronchiectasis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
91. Elborn JS, Johnston B, Allen F, Clarke J,McGarry J,Varghere G. Inhaled steroids in patients with bronchiectasis. Respir Med 1992; 86:121-4.
92. Tsang KW,Ho P, Lam W et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. AmJ Respir Crit Care Med 1998; 158:723-7.
93. Konstan MW, Byard PJ,Happel CL, Davies PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332:848-54.
94. Tamachi J, Chiyotani A, Kobayashi K, Sakai N, Kanemura T, Takizama T. Effect of indomethacin on bronchorrhoea in patients with chronic bronchitis, diffuse panbronchiolitis or bronchiectasis. AmRev Respir Dis 1992; 145:548-52.
95. Llewellyn-Jones CG, Johnson MM,Mitchell JL et al. In vivo study of indomethacin in bronchiectasis: effect on neutrophil function and lung secretion. Eur Respir J 1995; 8:1479-87.
96. Corless JA, Warburton CJ. Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
97. Hassan JA, Saadiah S, Roslan H, Zainudin BM. Bronchodilator response to inhaled b2 agonist and anticholinergic drugs in patients with bronchiectasis. Respirology 1999; 4:423-6.
98. Dowling RB, Rayner CFJ, Rutman A et al. Effect of salmeterol on Pseudomonas aeruginosa infection in respiratory mucosa. Am J Respir Crit Care Med 1997; 155:326-36.
99. Sheikh A, Nolan D, Greenstone K. Long-acting b2 agonists for bronchiectasis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
100. Lasserton T, Holt K, Evans D, Greenstone M. Anticholinergic therapy for bronchiectasis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
101. Steele K, Lasserson JA, Greenstone M. Oral methyl-xanthines for bronchiectasis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
102. Yoon W, Kim JK, Kim YH, Chung TW, Kang HK. Bronchial and non-bronchial systemic artery embolization for life-threatening haemoptysis: a comprehensive review. Radiographics 2002; 22:1395-409.
103. Corless JA,Warburton CJ. Surgery versus non-surgical treatment for bronchiectasis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford,Update Software, 2003.
104. Agasthian T, Deschamps C, Trostek VF, Allen MS, Pairolero PC. Surgical management of bronchiectasis. Am Thorac Surg 1996; 62:976-80.
105. Arhour M,Al-Kattan K,Ropay MA, Saja KF,Hajjar W, Al-Frayi AR. Current surgical therapy for bronchiectasis. World J Surg 1999; 23:1096-104.
106. Fujimoto T, Hillejan L, Stamatis G. Current strategy for surgical management of bronchiectasis. Am Thorac Surg 2001; 72:1711-15.
107. Mazieres J,Murris M, Didier A et al. Limited operation for severe multi-segmental bilateral bronchiectasis. Am Thorac Surg 2003; 75:382-7.
108. Annest JS, Kratz JM, Crawford FA. Current results of treatment of bronchiectasis. J Thorac Cardiovasc Surg 1982; 83:546-50.
109. Hosenpud JD, Bennett LE, Keck BM, Boueck MM, Novick RJ. The registry of the International Society for Heart and Lung Transplantation: seventeenth official report-2000. J Heart Lung Transplant 2000; 19:909-31.
110. Olivieri D,Ciaccia A,Marangio E,Marisco S,Todisco T, Del Vita M. Role of bromhexine in exacerbations of bronchiectasis. Respiration 1991; 58:117-121.
111. Ip M, Shum D, Lauder I, Lam WK, So SY. Effect of antibiotics on sputum inflammatory contents in acute exacerbations of bronchiectasis. Respir Med 1993; 87:449-54.
112. Chan TH,Ho SS, Lai CK et al. Comparison of oral ciprofloxacin and amoxycillin in treating infective exacerbations of bronchiectasis in Hong Kong. Chemotherapy 1996; 42:150-6.